Baxter International is an American healthcare company that has been around since the 1930s. It has grown to become a global leader in medical products, services and solutions, with a presence in more than 100 countries. With its strong financials, consistently growing revenues, and potential upside in its medical product lines, now is an ideal time to explore the potential of investing in Baxter International. The company has made significant investments in research and development over the past few years, resulting in a robust portfolio of products and services that can help it capitalize on the growing demand for healthcare solutions.
Furthermore, its ongoing cost-cutting initiatives and strategic acquisitions have allowed it to remain competitive in the healthcare industry. As such, it is well-positioned to take advantage of the growing demand for medical products and services, which is expected to continue for the foreseeable future. As a result, now is an opportune time to explore the potential of investing in Baxter International.
Exploring the Potential of Baxter International: Reasons to Invest Now:-
1. Cost Cutting Initiatives and Strategic Acquisitions
Baxter has made efforts to reduce its overhead and is looking to do more. For example, it believes that it can reduce its general and administrative expenses by $150 million in fiscal 2021. This will help the company boost its margins and improve its cash flow. Additionally, Baxter has a strong track record of making strategic acquisitions to grow its business and expand into new markets. For example, it recently acquired Swedish healthcare company Epsylon, which specializes in blood transfusion, blood storage, and blood management.
This acquisition expands Baxter’s presence in the blood management space. Baxter has also made acquisitions in the field of biopharmaceuticals, which is expected to see robust demand over the next few years. For example, the company acquired SynBio and its proprietary RAVICTM platform technology. This acquisition gave Baxter access to a portfolio of biotherapeutics, including RAVICTM-E, a biosimilar of Epogen and RAVICTM-G, a biosimilar of Neupogen. These products are expected to have strong demand, given that their respective branded equivalents are projected to lose patent protection in the next few years.
2. Growing Demand for Healthcare Solutions
The healthcare industry is expected to continue growing at a robust pace over the next few years. This is due to an increase in the demand for healthcare services and an aging population. The demand for healthcare services is expected to grow, due to a rising incidence of chronic illnesses and an increase in the incidence of diseases such as cancer. The incidence of chronic illnesses, such as diabetes and hypertension, is expected to increase due to changing demographic and behavioral trends. The aging population is also expected to contribute to the growing demand for healthcare services, as older adults tend to have more complex healthcare needs.
By 2025, the number of people above the age of 65 is expected to increase by 44% globally, while the number of people above the age of 80 is expected to increase by 73%. As a result, healthcare spending is expected to rise, given that the increase in the number of people requiring healthcare services will put pressure on healthcare systems. This growing demand for healthcare solutions is expected to have a positive impact on the prospects of Baxter International. The company is well-positioned to take advantage of this trend, given its wide portfolio of healthcare products and services.
3. Baxter International’s Product Portfolio
Baxter International’s product portfolio includes intravenous therapy and medication administration, blood transfusion and blood management, critical care, surgery, home health, biosurgery, infection prevention, and emergency response products. The company’s intravenous therapy and medication administration products include blood-draw devices, infusion pumps and monitors, blood management systems, and medication administration systems. Baxter’s blood transfusion and blood management products include blood transfusion devices, blood components, blood bags, and blood management systems.
Critical care products include respiratory, monitoring and detection systems, and pressure care systems. Surgery products include anaesthesia, surgical, and surgical navigation systems. Home health products include pressure relief and wound care products. Biosurgery products include surgical tools, tissue management products, and disinfection products. Infection prevention products include microbiology products, protective isolation products, and skin and woundcare products. Emergency response products include emergency response products, emergency intervention products, and disaster preparedness and response products.
4. Opportunities for Growth
Baxter’s wide product portfolio, diverse customer base, and presence in several therapeutic areas offer plenty of opportunities for growth. The company’s product portfolio includes several products that are expected to see robust demand over the next few years. In addition, Baxter has a strong presence in several therapeutic areas, such as critical care and surgery, where the demand for healthcare services is expected to grow over the next few years.
For example, the demand for critical care products is expected to grow over the next few years, given that the number of critical care patients is expected to increase over this period. Furthermore, the number of surgeries is expected to grow over the next few years, given that the number of surgeries is expected to rise over this period. This demand for surgeries is expected to drive demand for surgery products, which is expected to benefit Baxter International.
5. Other Reasons to Invest in Baxter International Now
Baxter International’s strong financial metrics indicate that it has the potential to deliver strong returns on investment. The company’s net sales and gross profit have grown consistently over the last few years. Furthermore, Baxter International reported a strong balance sheet. The company has an impressive debt-to-equity ratio of 0.8 and an interest coverage ratio of 46.9, indicating strong financial health.
In addition, the healthcare industry is expected to grow steadily over the next few years, driven by rising demand for healthcare services and an increase in the number of surgeries. This growth in the demand for healthcare solutions is expected to help Baxter International expand its business and deliver robust returns to its investors.
Conclusion
Baxter International is an American healthcare company that has been around since the 1930s. It has grown to become a global leader in medical products, services and solutions, with a presence in more than 100 countries. The company has made significant investments in research and development over the past few years, resulting in a robust portfolio of products and services that can help it capitalize on the growing demand for healthcare solutions.
Furthermore, its cost-cutting initiatives and strategic acquisitions have allowed it to remain competitive in the healthcare industry. As such, it is well-positioned to take advantage of the growing demand for medical products and services, which is expected to continue for the foreseeable future. As a result, now is an opportune time to explore the potential of investing in Baxter International.
Also read:- 5 Reasons to Invest in Apple: An In-Depth Analysis